This is the HS OBTAIN study with Sanofi assessing the efficacy and safety of an anti-TNF-OX40L NANOBODY molecule, SAR442970 in participants with moderate to severe hidradenitis suppurativa.
This is the HS OBTAIN study with Sanofi assessing the efficacy and safety of an anti-TNF-OX40L NANOBODY molecule, SAR442970 in participants with moderate to severe hidradenitis suppurativa.